Bamco Inc. NY Has $47.35 Million Stock Position in Axonics, Inc. (NASDAQ:AXNX)

Bamco Inc. NY reduced its stake in shares of Axonics, Inc. (NASDAQ:AXNX) by 61.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 686,565 shares of the company’s stock after selling 1,111,398 shares during the period. Bamco Inc. NY owned approximately 1.35% of Axonics worth $47,352,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. NBC Securities Inc. grew its stake in shares of Axonics by 106.4% in the fourth quarter. NBC Securities Inc. now owns 673 shares of the company’s stock valued at $41,000 after buying an additional 347 shares in the last quarter. Headlands Technologies LLC bought a new position in Axonics during the fourth quarter worth $53,000. Whittier Trust Co. boosted its position in Axonics by 59.1% during the first quarter. Whittier Trust Co. now owns 1,142 shares of the company’s stock worth $79,000 after purchasing an additional 424 shares during the period. Sentry Investment Management LLC bought a new position in Axonics during the fourth quarter worth $125,000. Finally, Inspirion Wealth Advisors LLC bought a new position in Axonics during the first quarter worth $207,000. 99.48% of the stock is currently owned by institutional investors and hedge funds.

Axonics Trading Up 0.4 %

Axonics stock traded up $0.30 during midday trading on Friday, reaching $68.49. The company’s stock had a trading volume of 499,351 shares, compared to its average volume of 318,153. Axonics, Inc. has a 52 week low of $48.30 and a 52 week high of $69.68. The business has a 50-day moving average price of $67.48 and a 200-day moving average price of $67.72. The stock has a market cap of $3.49 billion, a PE ratio of -214.03 and a beta of 0.83.

Axonics (NASDAQ:AXNX) last released its earnings results on Tuesday, April 30th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.32). Axonics had a negative net margin of 4.12% and a negative return on equity of 2.58%. The business had revenue of $91.41 million during the quarter, compared to the consensus estimate of $89.79 million. During the same quarter in the prior year, the firm earned ($0.19) EPS. The business’s revenue was up 29.4% on a year-over-year basis. As a group, research analysts predict that Axonics, Inc. will post 0.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a research note on Monday, May 6th. Eight investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $69.78.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.